Overview GAIA reported positive results from a randomized controlled trial published in Psychological Medicine, demonstrating that attexis significantly reduced ADH...
GAIA and Daiichi Sankyo Europe Partner to Commercialize Digital Therapeutic for Hypercholesterolemia
Overview GAIA and Daiichi Sankyo Europe have entered an exclusive strategic partnership to commercialize lipodia, a digital therapeutic designed to support adults living with hyperchol...
Overview MOBE has partnered with and invested in Sidekick Health to strengthen its whole-person care model for individuals managing multiple chronic conditions (MCC). The collaboration com...
Overview Lumos Labs has received FDA 510(k) clearance for LumosityRx, a prescription digital therapeutic (PDT) designed to improve attention in adults aged 22 to 55 with ADHD. Built o...
